TY - JOUR
T1 - Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains
AU - Guo, Lin
AU - Kim, Hong Joo
AU - Wang, Hejia
AU - Monaghan, John
AU - Freyermuth, Fernande
AU - Sung, Julie C.
AU - O'Donovan, Kevin
AU - Fare, Charlotte M.
AU - Diaz, Zamia
AU - Singh, Nikita
AU - Zhang, Zi Chao
AU - Coughlin, Maura
AU - Sweeny, Elizabeth A.
AU - DeSantis, Morgan E.
AU - Jackrel, Meredith E.
AU - Rodell, Christopher B.
AU - Burdick, Jason A.
AU - King, Oliver D.
AU - Gitler, Aaron D.
AU - Lagier-Tourenne, Clotilde
AU - Pandey, Udai Bhan
AU - Chook, Yuh Min
AU - Taylor, J. Paul
AU - Shorter, James
N1 - Funding Information:
We thank Dorothee Dormann, Mike Rosen, Richard Wheeler, Nancy Bonini, and Ben Black for suggestions and support, and we thank Philip Van Damme, Gideon Dreyfuss, Greg Petsko, and Steve McKnight for reagents. Our work was supported by an EMF/AFAR fellowship (L.G.), an AARF fellowship (L.G.), an ALSA Milton Safenowitz fellowship (F.F.), a MGH ECOR Tosteson fellowship (F.F.), AHA fellowships (E.A.S., M.E.J., and C.B.R), NIH grants T32GM008275 (E.A.S.), T32GM071339 (M.E.D.S.), F31NS079009 (M.E.D.S.), R01NS081303 (U.B.P.), R21NS100055 (U.B.P.), R21NS094921 (U.B.P.), R35NS097263 (A.D.G.), R01NS087227 (C.L.-T.), R01GM069909 (Y.M.C.), R35NS097974 (J.P.T.), R21NS090205 (J.S.), R01GM099836 (J.S.), Target ALS (L.G., M.E.J., C.L.-T., J.P.T., and J.S), the Welch Foundation (Y.M.C.), UTSW Endowed Scholars Program (Y.M.C.), HHMI (J.P.T.), ALS FindingACure (C.L.-T.), ALSAC (J.P.T.), ALSA (J.S.), MDA (J.S.), and the Packard Center for ALS Research (J.P.T. and J.S.).
Funding Information:
We thank Dorothee Dormann, Mike Rosen, Richard Wheeler, Nancy Bonini, and Ben Black for suggestions and support, and we thank Philip Van Damme, Gideon Dreyfuss, Greg Petsko, and Steve McKnight for reagents. Our work was supported by an EMF/AFAR fellowship (L.G.), an AARF fellowship (L.G.), an ALSA Milton Safenowitz fellowship (F.F.), a MGH ECOR Tosteson fellowship (F.F.), AHA fellowships (E.A.S., M.E.J., and C.B.R), NIH grants T32GM008275 (E.A.S.), T32GM071339 (M.E.D.S.), F31NS079009 (M.E.D.S.), R01NS081303 (U.B.P.), R21NS100055 (U.B.P.), R21NS094921 (U.B.P.), R35NS097263 (A.D.G.), R01NS087227 (C.L.-T.), R01GM069909 (Y.M.C.), R35NS097974 (J.P.T.), R21NS090205 (J.S.), R01GM099836 (J.S.), Target ALS (L.G., M.E.J., C.L.-T., J.P.T., and J.S), the Welch Foundation (Y.M.C.), UTSW Endowed Scholars Program (Y.M.C.), HHMI (J.P.T.), ALS FindingACure (C.L.-T.), ALSAC (J.P.T.), ALSA (J.S.), MDA (J.S.), and the Packard Center for ALS Research (J.P.T. and J.S.).
Funding Information:
Conceptualization, L.G., H.J.K., H.W., J.M., F.F., J.C.S., C.L.-T., U.B.P., Y.M.C., J.P.T., and J.S.; Methodology, L.G., H.J.K., H.W., J.M., F.F., J.C.S., J.A.B., O.D.K., A.D.G., C.L.-T., U.B.P., Y.M.C., J.P.T., and J.S.; Software, O.D.K.; Validation, L.G., H.J.K., H.W., J.M., F.F., J.C.S., K.O.D., C.M.F., Z.D., N.S., M.C., E.A.S., M.E.D.S., C.B.R., O.D.K., and J.S.; Formal Analysis, L.G., H.J.K., O.D.K., and J.S.; Investigation, L.G., H.J.K., H.W., J.M., F.F., J.C.S., K.O.D., C.M.F., Z.D., N.S., M.C., E.A.S., M.E.D., C.B.R., O.D.K., and J.S.; Resources, L.G., H.J.K., H.W., J.M., F.F., J.C.S., C.M.F., Z.D., N.S., Z.C.Z., E.A.S., M.E.D.S., M.E.J., U.B.P., Y.M.C., and J.S.; Writing – Original Draft, L.G., H.J.K., H.W., J.M., J.C.S., J.A.B., U.B.P., Y.M.C., J.P.T., and J.S.; Writing – Review & Editing, L.G., H.J.K., H.W., J.M., F.F., J.C.S., C.M.F., O.D.K., C.L.-T., U.B.P., Y.M.C., J.P.T., and J.S.; Visualization, L.G., H.J.K., H.W., J.M., F.F., J.C.S., J.P.T., and J.S.; Supervision, J.A.B., A.D.G., C.L.-T., U.B.P., Y.M.C., J.P.T., and J.S.; Project Administration, J.A.B., A.D.G., C.L.-T., U.B.P., Y.M.C., J.P.T., and J.S.; Funding Acquisition: L.G., F.F., E.A.S., M.E.D.S., M.E.J., C.B.R., J.A.B., A.D.G., C.L.-T., U.B.P., Y.M.C., J.P.T., and J.S.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/4/19
Y1 - 2018/4/19
N2 - RNA-binding proteins (RBPs) with prion-like domains (PrLDs) phase transition to functional liquids, which can mature into aberrant hydrogels composed of pathological fibrils that underpin fatal neurodegenerative disorders. Several nuclear RBPs with PrLDs, including TDP-43, FUS, hnRNPA1, and hnRNPA2, mislocalize to cytoplasmic inclusions in neurodegenerative disorders, and mutations in their PrLDs can accelerate fibrillization and cause disease. Here, we establish that nuclear-import receptors (NIRs) specifically chaperone and potently disaggregate wild-type and disease-linked RBPs bearing a NLS. Karyopherin-β2 (also called Transportin-1) engages PY-NLSs to inhibit and reverse FUS, TAF15, EWSR1, hnRNPA1, and hnRNPA2 fibrillization, whereas Importin-α plus Karyopherin-β1 prevent and reverse TDP-43 fibrillization. Remarkably, Karyopherin-β2 dissolves phase-separated liquids and aberrant fibrillar hydrogels formed by FUS and hnRNPA1. In vivo, Karyopherin-β2 prevents RBPs with PY-NLSs accumulating in stress granules, restores nuclear RBP localization and function, and rescues degeneration caused by disease-linked FUS and hnRNPA2. Thus, NIRs therapeutically restore RBP homeostasis and mitigate neurodegeneration. Nuclear-import receptors can reverse phase separation and aggregation of proteins with prion-like domains, including FUS and TDP-43, to mitigate neurodegeneration in vivo.
AB - RNA-binding proteins (RBPs) with prion-like domains (PrLDs) phase transition to functional liquids, which can mature into aberrant hydrogels composed of pathological fibrils that underpin fatal neurodegenerative disorders. Several nuclear RBPs with PrLDs, including TDP-43, FUS, hnRNPA1, and hnRNPA2, mislocalize to cytoplasmic inclusions in neurodegenerative disorders, and mutations in their PrLDs can accelerate fibrillization and cause disease. Here, we establish that nuclear-import receptors (NIRs) specifically chaperone and potently disaggregate wild-type and disease-linked RBPs bearing a NLS. Karyopherin-β2 (also called Transportin-1) engages PY-NLSs to inhibit and reverse FUS, TAF15, EWSR1, hnRNPA1, and hnRNPA2 fibrillization, whereas Importin-α plus Karyopherin-β1 prevent and reverse TDP-43 fibrillization. Remarkably, Karyopherin-β2 dissolves phase-separated liquids and aberrant fibrillar hydrogels formed by FUS and hnRNPA1. In vivo, Karyopherin-β2 prevents RBPs with PY-NLSs accumulating in stress granules, restores nuclear RBP localization and function, and rescues degeneration caused by disease-linked FUS and hnRNPA2. Thus, NIRs therapeutically restore RBP homeostasis and mitigate neurodegeneration. Nuclear-import receptors can reverse phase separation and aggregation of proteins with prion-like domains, including FUS and TDP-43, to mitigate neurodegeneration in vivo.
KW - ALS
KW - disaggregase
KW - FTD
KW - FUS
KW - hnRNPA1
KW - Karyopherin-β2
KW - neurodegeneration
KW - Nuclear-important receptor
KW - phase transition
KW - TDP-43
UR - http://www.scopus.com/inward/record.url?scp=85045775165&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2018.03.002
DO - 10.1016/j.cell.2018.03.002
M3 - Article
C2 - 29677512
AN - SCOPUS:85045775165
SN - 0092-8674
VL - 173
SP - 677-692.e20
JO - Cell
JF - Cell
IS - 3
ER -